Table 2.

Characteristics of included studies

Study	Registration number	Country	Study design	Sample size (treatment/control)	Age (years) (mean±SD)	Sex (male/female)	BMI (kg/m2)	eGFR (mL/min/1.73 m2)	Duration (weeks)
Dapagliflozin
Kohan et al33	NCT00663260	Multicenter	RCT	Placebo: 84	67±8.6	53/31	Reported as number	Reported as number	104
				5 mg: 83	66±8.9	55/28
				10 mg: 85	68±7.7	56/29
Satirapoj et al34	TCTR20180424002	Thailand	RCT	Placebo: 29	59.9±1.6	8/21	27.9±0.9	87.3±2.9	12
				Dapagliflozin: 28	55.9±1.4	17/11	28.4±0.8	88.7±3.1
Empagliflozin
Zinman et al38	NCT01131676	Multicenter	RCT	Placebo: 2333	63.2±8.8	1680/653	30.7±5.2	73.8±21.1	206
				10 mg: 2345	63.0±8.6	1653/692	30.6±5.2	74.3±21.8
				25 mg: 2342	63.2±8.6	1683/659	30.6±5.3	74.0±21.4
Barnett et al31	NCT01164501	Multicenter	RCT (stage 2 CKD)	Placebo: 95	62.6±8.1	56/39	30.8±5.6	71.8±10.2	52
				10 mg: 98	63.2±8.5	60/38	32.4±5.4	70.8±10.3
				25 mg: 97	62.0±8.4	61/36	31.3±5.8	72.3±11.2
			RCT (stage 3 CKD)	Placebo: 187	65.1±8.2	106/81	30.3±5.3	44.3±10.3	52
				25 mg: 187	64.6±8.9	107/80	30.2±5.3	45.4±10.2
Canagliflozin
Yale et al53	NCT01064414	Multicenter	RCT	Placebo: 90	68.2±8.4	57/33	33.1±6.5	40.1±6.8	52
				100 mg: 90	69.5±8.2	58/32	32.4±5.5	39.7±6.9
				300 mg: 89	67.9±8.2	48/41	33.4±6.5	38.5±6.9
Sotagliflozin
Cherney et al32	NCT03242252	Multicenter	RCT	Placebo: 260	69.3±8.1	149/111	32.5±5.2	44.8±8.4	26
				200 mg: 263	69.6±7.5	143/120	32.3±5.7	45.2±8.1
				400 mg: 264	69.5±8.2	152/112	32.4±5.2	45.1±7.9
Ipragliflozin
Tanaka et al35	UMIN000016563	Japan	RCT	Control: 15	62.5±13.5	7/8	31.4±5.1	67.9±16.9	12
				Ipragliflozin: 15	59.1±11.2	8/7	30.5±7.0	67.3±18.2
Tofogliflozin
Terauchi et al36	NCT02201004	Japan	RCT	Control: 70	56.4±10.0	48/22	26.9±3.9	79.5±17.0	16
				Tofogliflozin: 141	59.1±10.8	59/82	25.8±3.5	79.7±19.8

BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RCT, randomized controlled trial.